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Implementation research (IR) is growing in recognition as an important generator of practical knowledge that can
be translated into health policy. With its aim to answer questions about how to improve access to interventions
that have been shown to work but have not reached many of the people who could benefit from them, IR
involves a range of particular ethical considerations that have not yet been comprehensively covered in
international guidelines on health research ethics. The fundamental ethical principles governing clinical research
apply equally in IR, but the application of these principles may differ depending on the IR question, context, and
the nature of the proposed intervention. IR questions cover a broad range of topics that focus on improving health
system functioning and improving equitable and just access to effective health care interventions. As such, IR
designs are flexible and often innovative, and ethical principles cannot simply be extrapolated from their
applications in clinical research. Meaningful engagement with all stakeholders including communities and research
participants is a fundamental ethical requirement that cuts across all study phases of IR and links most ethical
concerns. Careful modification of the informed consent process may be required in IR to permit study of a needed
intervention. The risks associated with IR may be difficult to anticipate and may be very context-specific. The
benefits of IR may not accrue to the same groups who participate in the research, therefore justifying the risks
versus benefits of IR may be ethically challenging. The expectation that knowledge generated through IR should be
rapidly translated into health policy and practice necessitates up-front commitments from decision-makers to
sustainability and scalability of effective interventions. Greater awareness of the particular ethical implications of the
features of IR is urgently needed to facilitate optimal ethical conduct of IR and uniform ethical review.Introduction
Implementation research (IR) is growing in importance
and recognition: there is an increasing funding from a
range of donors/sponsors for this research area, leading
scientific journals have established sections promoting
the publication of such research, and it contributes in-
creasingly to the evidence-base used by the World
Health Organization (WHO), which promotes, supports,
publishes, and evaluates such research [1]. With its aim
to answer questions about how to improve access to in-
terventions that have been shown to work but have not
reached many of the people who could benefit from* Correspondence: vijay.gopichandran@gmail.com
†Equal contributors
1Department of Community Medicine, ESIC Medical College and
Postgraduate Institute of Medical Sciences and Research, KK Nagar, Chennai
600078, India
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This artic
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zethem, IR involves a range of particular ethical consider-
ations that have not yet been comprehensively covered
in most international guidelines on health research
ethics [2, 3]. The draft of the Council for International
Organizations of Medical Sciences (CIOMS) guidelines
which is currently under revision as well as its commen-
tary does briefly allude to ethical considerations in the
conduct of cluster randomized trials (CRT), but thus far
there has been no comprehensive discussion or guideline
regarding the application of ethical principles in IR in
general or in relation to study designs beyond CRTs [4].
In response to the need for more clarity and guidance
about the ethical implications throughout the IR process,
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tion Research Toolkit, as a practical guide for IR re-
searchers and ethics committees to facilitate optimal
study design, conduct, and review. The training tool was
developed through a consultative process launched in
Geneva in which IR experts, philosophers, ethics com-
mittee members, and public health practitioners met to
identify the ethical issues in IR, define the course con-
tent and the format of the training workshops. The tool
was further developed through small group work with
the support of an expert in adult training methods. The
tool has been validated in two pilot workshops in Asia
and Africa. The list of experts who contributed to the
development of the Toolkit, apart from the authors of
this manuscript, can be found in the Acknowledgements
section.
This manuscript is constructed around the concepts
identified during the development and piloting of the
Ethics in Implementation Research Toolkit and aims to
highlight the differences in application of ethical princi-
ples between clinical and implementation research, and
to highlight the current gaps in ethical guidelines for the
conduct of IR.
Background
IR involves increasing the understanding of how to im-
prove access to health products and strategies that are
already available and have been shown to work, but re-
main beyond the reach of many of the people who could
benefit from them. IR therefore provides the link be-
tween what should happen in theory and what actually
happens in practice. It is rooted in the identification of
practical problems facing disease control programmes
and in finding solutions which improve access to health
interventions and lead to better health outcomes. IR ad-
dresses different aspects of implementation including so-
cial and contextual factors (poverty, environment,
culture), the process of implementation (which approach
best answers the implementation issue?) or the out-
comes of implementation (clinical/process end points).
For example, in case of a new vaccine for prevention of
dengue, basic science and traditional clinical research
address vaccine development and safety and efficacy
testing. IR then addresses the questions of accessibility,
acceptability, appropriateness, and feasibility in the com-
munities where the vaccine is needed. IR questions,
however, are not always related to a clinical disease en-
tity or implementation of a treatment or prevention pro-
gram. IR also addresses process issues in health care
delivery, as well as cost-effectiveness, policy uptake and
implementation, health education etc. IR therefore draws
on a wide variety of research approaches to address the
diverse research questions. The research designs there-
fore are not restricted to traditional trial designs, butinclude methods such as participatory action research
(PAR),1 qualitative design, and effectiveness implementa-
tion hybrid designs 2. Flexibility is a great advantage in
IR as the research question largely drives the design, the
research process is iterative, and the findings at each
stage feed back into the design. IR is usually carried out
in close collaboration between researchers and disease
control programme staff or policy-makers. The costs are
generally modest, yet IR has the potential for a large
magnifier effect, as effective implementation expands the
impact of health interventions delivered by programmes.
As a pre-requisite therefore to the design of a successful
implementation strategy, the clinical/public health prob-
lem must be identified, the epidemiology of the disease/
health status must be understood, and a situation ana-
lysis must be performed to identify why access is sub-
optimal, and what the actual bottlenecks/gaps in care
delivery are (not merely presumed), such that interven-
tions can be targeted to reduce these bottlenecks/gaps.
In the case of adoption of a successful intervention from
one country by another country or scaling-up of inter-
ventions from a pilot phase to a wide area, a local situ-
ational analysis should be carried out to determine
differences and similarities between the communities
where an intervention has been successfully imple-
mented and the communities in which the intervention
will be tested. IR is relevant when this analysis shows
important differences but points to the proposed inter-
vention as the most appropriate strategy, or justifies full
scale implementation of the intervention [5]. Awareness
of the appropriate application of ethical principles in IR
is important in study design and data generation to
ensure ethical conduct of IR and to effectively contribute
to health system strengthening. In the planning stages,
researchers must also be able to effectively communicate
their consideration of the ethical principles to research
ethics committees, who must also have insight into the
adaptations of ethical principles required in IR (as
opposed to traditional clinical research) such that
protocols are appropriately and fairly reviewed.
Are there ethical considerations which apply particularly
to implementation research?
IR is aimed at identifying the best process to implement
and scale-up research evidence, whereas biomedical and
clinical research focuses on establishing the evidence.
This fundamental difference between clinical and imple-
mentation research necessitates a modification in the
application of ethical principles in their conduct as
highlighted in Table 1.
Most researchers and research ethics committees are
familiar with the ethical challenges posed by traditional
clinical research, which emphasizes respect for individ-
ual autonomy and the importance of individual informed
Table 1 Differences between clinical and implementation research which impact application of ethical principlesa
Domain Clinical research Implementation research
Research participants Individuals Countries, institutions, communities, and individuals
Informed consent Informed consent by competent individuals, assent
by minors and consent by legally authorized
representatives
Consent may be difficult to obtain in cluster randomized trial
design. There may be a need for a two level
consent—consent for randomization from gatekeepers and
consent for participation at the individual level. Sometimes
individual consent may not be feasible. However, gatekeeper
consent does not replace the need for individual consent.
Ethical committee should oversee the informed consent
requirement and process
Equipoise Clinical equipoise Clinical as well as contextual equipoise (genuine
uncertainty that the implementation will work in a new
context as well as whether the implementation package
will work at all)
Pre-requisites Understanding of disease pathophysiology
Intervention aimed at disease-specific management
Identification of population health needs
Understanding relative priority of need for intervention
within local context
Community engagement to understand community needs,
ensure scalability, and sustainability
Research conditions Generally controlled research environment Real-life or pragmatic research environment
Research designs Cross-sectional, case-control studies,
Cohort studies, randomized clinical trials
Cluster randomized trials
Pragmatic, mixed methods, effectiveness implementation
hybrid designs, participatory action research, quasi-
experimental design, realist review
Integration within health system Often, there is no a priori plan for health system
integration. Findings of clinical research go through
IR before integration into health system
IR has a strong health system strengthening focus. It creates
horizontal integration into the health system. There is an ethical
imperative for health system integration
Predominant research disciplines Physiology, genetics, biochemistry, and other basic
sciences, epidemiology, clinical medicine
Anthropology
Economics
Epidemiology
Political science
Public health
Sociology
Control groups In most epidemiological designs, control groups are
required. But some phase 1 clinical trials and
observational studies may not require control groups
Having a no intervention control group may not be
acceptable. Alternative designs of quasi-experimental
studies do not require a control group
Boundary between research and
clinical care
This boundary is usually clear, but may be unclear in
case of therapeutic misconception especially in
cancer trials
Is often unclear, because the intervention is of proven
efficacy
Types of research question Efficacy and safety of a therapeutic strategy in the
individual
Operationalization of an intervention in local context
Implementation of an intervention in local context prior
to scale-up
Policy analysis
Health system functioning at multiple levels
Anticipated outcomes Well-defined hypothesis at the beginning of the
clinical research. Expected outcomes clearly stated.
Multifaceted holistic impact on health systems
functioning with regard to intervention tested.
Sometimes outcomes may be unexpected
Risks assumed by: Mostly, the risks are for the study participants.
However, families and communities may also be
affected in specific contexts
Usually population level risks. Moreover, the people
getting the benefits and people suffering the risks may
be different.
Benefits accrued by: Benefits accrue to the participants, the community.
The research finding may be a common good
Individuals, communities, health system, institutions may
benefit. The research findings may be common good.
The people accruing benefits may be different from
those who suffer risks
Generalizability Generalizability is sometimes possible in multicentric
and well sampled studies, however most studies are
specific to the target populations.
Generalizability may be limited by contextual factors.
However, findings may be generalizable to similar
contexts
Social justice implications Social justice is usually not a primary consideration.
However, justice considerations are required in
selection of research participants. Research on
vulnerable participants is often contentious because
of compromised autonomy and other logistics
Social justice considerations are primary. Working with
vulnerable groups essential to understand
implementation issues in these groups so that the
intervention can reach them
aDeveloped from References [2, 6–13, 20, 43]
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ical equipoise. Clinical research is usually carried out to
answer a focused clinical question, under controlled cir-
cumstances, in a well-defined subject cohort with rigid
inclusion and exclusion criteria. In IR, in contrast, be-
cause the goal is to generate knowledge that leads to
wide-scale implementation of interventions in new con-
texts, the priority focus is different from that of clinical
research [2, 6–13]. IR tends to occur in real-world cir-
cumstances to test the feasibility and effectiveness of an
intervention in real-life situations and not under the
controlled environs of clinical research, therefore the
boundary between research and clinical care/public
health practice can be quite blurred. The implementa-
tion ethics issues that arise in the context of IR may also
be distinguished from those that arise in the context of
programmatic implementation [14]. A priority in IR is
broad inclusion of research subjects, specifically includ-
ing vulnerable populations to optimize equity and justice
in access to the intervention. An ultimate goal of IR is to
generate knowledge that will be translated into health
policy and health action, and therefore studies must be
conducted with the vision of sustainable scale-up and
roll-out of effective interventions. Although many ethical
principles are common to biomedical research and IR,
there may be some differences in the way these princi-
ples are applied. The key ethical issues relating to IR
may be broadly divided into those that arise during the
planning phase, the implementation phase, and the post-
research phase. Although some ethical issues cut acrossFig. 1 Ethical considerations in various phases of Implementation Researchmultiple phases, for the purposes of this review we will
discuss the issues as illustrated in Fig. 1. A case study is
presented in Table 2 to illustrate the relevance of such
ethical issues in the conduct of IR (case adapted from
published experiences for the didactic purposes of this
manuscript) [15].
Ethical concerns in the planning phase of IR
Responsiveness of IR
Problems addressed by IR must be of high local priority
in order to justify the research [16]. One could argue
that the requirement for responsiveness is greater from
IR compared with clinical research as IR should address
priority health needs whereas clinical research is con-
cerned more with proof of principle, and wider applica-
tion should be tested with subsequent IR. Conversely,
when there is an available intervention for an important
unmet health need in a community, there is an ethical
imperative to conduct IR to try to address the imple-
mentation barriers. As such, IR studies are often
commissioned by local health authorities. The know-
ledge of which problems are indeed local priorities relies
on epidemiology and health data reporting, which may
not always be optimal in resource-challenged environ-
ments. Engagement with local health experts and com-
munities is therefore essential in the planning stages of
IR to determine whether a health problem is indeed per-
ceived to be a local priority. If a particular problem is
not perceived to be a local health priority, the ethics of
conducting IR becomes questionable [17].
Table 2 A case study illustrating the multiple ethical challenges
arising in implementation research
Implementation research of strategies to improve vaccine coverage in
children in nomadic populations
Study description. Country X had a low rate of vaccine coverage largely
because a significant group of nomadic populations were not reached
by the routine vaccination strategies. A basic needs assessment was
performed among the nomadic populations and found their vaccine
coverage rate to be very low. In addition, the assessment found that
insufficient knowledge of the location of the nomadic populations, lack
of logistical support and lack of community engagement in the
vaccination drives were important reasons for poor coverage. In order
to overcome these problems, an implementation research study was
planned. Special Outreach Teams (SOTs) were trained and deployed to a
selected sample of known nomadic groups. These SOTs were provided
with all logistical requirements such as vehicles, ice boxes, vaccine
stocks, and temperature logs. They were also trained to engage with
the communities, to deliver the vaccinations to the children under five
according to schedule and also to collect data on the existing level of
vaccine coverage, numbers vaccinated, documentation of feasibility
challenges, and costs. The SOTs coordinated their work with the routine
health care workers in the communities where these nomadic groups
were stationed at the time of contact. In addition, a small subsample of
the nomadic groups were invited to participate in a mobile phone-
based GPS tracking study to assess the feasibility and utility of locating
the nomadic groups in real-time. Solar powered battery packs were
provided to the key members of the community who held the GPS
tracking mobile phone. Their GPS coordinates were relayed to the SOTs
so that they can deliver their services effectively.
Ethical issues. This implementation research study brings out several
important ethical considerations. There is an ethical imperative to
engage and work with this special marginalized group in order to
increase coverage of vaccination as it is the duty of the health system
to protect and promote their health and also in order to more
effectively protect the rest of the community with whom the nomadic
groups will come in contact. Equipoise to justify the conduct of the
study lies primarily in the uncertainty of how the intervention will be
taken up and effective within this context as it is known that the
vaccinations are effective from other populations. Despite this fact,
however, effectiveness of the vaccine should be tracked in this new
population as there may be modifiers of the effect, e.g., nutritional
status etc. that may also require ancillary care. The findings of the study
will help understand the feasibility and acceptability of the intervention
among nomadic communities thus facilitating the implementation of
the vaccination coverage campaign. Community engagement is a key
ethical consideration in this context. Marginalized communities like
these have inherent mistrust in health systems and community
engagement helps build trust. Identification of appropriate gatekeepers
of the community by appropriate selection process will facilitate both
the informed consent process as well as representation of long-term
voices of the communities. The tracking of the position of the nomadic
groups for the sake of facilitating the vaccination process using the GPS
tracking system is a significant intrusion into the privacy of the communities.
This needs to be carefully weighed and balanced against the benefits of
enhanced vaccine coverage and reduced child mortality because of that.
Moreover, confidentiality of the GPS tracking data should be clearly
maintained. Issues of sharing the GPS tracking position with local health
system, other parties who may be interested to track them for other
purposes etc. needs to be carefully deliberated. In addition, it is likely that
many other health needs would be identified in these communities, raising
the ethical issues associated with ancillary care responsibilities.
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Equipoise is an important ethical imperative in the con-
duct of research, it is required to justify any potential
risk to research subjects. Clinical equipoise refers to the
fact that investigators conducting a randomizedcontrolled trial do not know in advance if an interven-
tion is better than what it is being compared with. In IR,
however, such clinical equipoise is generally not present
(e.g., a medication is known to cure malaria), but in-
stead, situational or contextual equipoise justifies the
conduct of IR, i.e., there remains genuine doubt whether
a new and untested package of interventions will work
in a specific context [18]. To ethically justify IR, there-
fore, equipoise regarding the effectiveness of the imple-
mentation processes must be preserved.Study design
A balanced discussion about study design is important
before embarking on an IR study to weigh the ethical
obligation to ensure scientific standards are maintained
against the ethical demands of equity and justice [2, 19].
Though the randomized controlled trial is considered
the gold standard in clinical research, health system
strengthening interventions often do not lend them-
selves to such a design. Many different study designs,
often with multidisciplinary involvement, have been used
in IR, each raising particular ethical concerns [17]. Both
qualitative and quantitative methods are used in IR and
often within the same study. Examples of specific and
different ethical considerations may arise with each
method as outlined in Table 3. CRTs are often used in
health systems research, but when a public health inter-
vention is known to be effective, withholding the
intervention from those randomized to the control arm
is ethically problematic [4, 20, 21]. As a compromise, a
stepped-wedge approach is sometimes justified to ad-
dress this dilemma in CRTs, as this may mirror the real-
world scale-up process [22]. In a stepped-wedge design,
an intervention is delivered sequentially to groups of
participants with the goal of ultimately including all
participants, however in the early stages some groups do
not receive the intervention and therefore are analogous
to controls, which may pose an ethical challenge even if
short-term because for that short period of time the par-
ticipants are deprived of the proven intervention [23].
Alternatively, quasi-experimental designs where a con-
trol group may not be included may be ethically more
acceptable in IR, but the scientific rigor and validity may
be questioned [24]. The use of random allocation, with-
out consideration of the specific needs and vulnerabil-
ities of the participants, raises concerns of justice and
equity. Other appropriate study designs for IR include
pragmatic designs, hybrid and mixed methods designs,
and open-label demonstration projects which may each
have specific ethical issues that will require careful con-
sideration at the planning stage [25–27]. Engagement
with all stakeholders is crucial to develop the most
effective and fair study design.
Table 3 Ethical issues relating to examples of implementation research designsa
IR design Features Example Ethical concerns
Cluster randomized trials (group
randomized, place-based, community
wide intervention trials)
-Random allocation of groups or
“clusters” to study arms and
outcomes are measured in
individual subjects and at
community level
-Randomization of clusters of
obstetrics unit staff to education
on hand washing or usual
practice, measurement of rates of
puerperal sepsis in women
delivering at study clinics
-Different units of intervention and
outcomes measurement
-Consent before and after
randomization, whom to consent?
-Choice of gatekeepers
-No opt-out option within cluster
-Risk: benefit balance
-Ethics of randomization to known
intervention, equipoise,
-Identification of vulnerable groups
Effectiveness-implementation
hybrid trials
-Assess both effectiveness and
implementation strategy
simultaneously
-Identify
intervention—implementation
interactions
-Evaluate impact of ITN on
reduction of malaria and assess
robustness of availability and
uptake of ITNs in the community
-The trade-off between the
scientific rigor required for
effectiveness assessment and the
realistic contextual considerations
required for implementation is an
important ethical consideration
Mixed-methods research -Use of both qualitative and
quantitative methods
-Understands various perspectives
-Rationales: “participant
enrichment”, “instrument validity”,
implementation validity”,
“meaning enhancement”
-Integration of HIV and TB
management in single
clinics—patient experience
(qualitative) and adherence
(quantitative)
-The trade-off between the scientific
rigor required for quantitative
methods and the realistic contextual
considerations required for the
qualitative component
Participatory action research -Research question, design, and
data collection in a participative
manner by the research
participants
-“Bottom-up” approach
-Peer support groups to improve
adherence to ARV in HIV +
subjects
-There is a need for community
engagement to ensure
responsiveness, sustainability, and
scalability
Pragmatic trials -Effects of intervention in routine
practice
-Maximize variability of settings,
practitioners, patients
-Introduction of community
health workers for home
management of malaria
-There may be concerns of standards
of care and ancillary care, which in
pragmatic conditions may be
ethically debatable.
Quasi-experimental study -Real-life conditions
-With or without control group
No randomization
-Open label demonstration
project of effectiveness of self-
reported use of pre-exposure
prophylaxis for HIV
-There is a concern regarding
scientific rigor of the research
Realist view -Analysis of how and why an
intervention works in a context
combining theory and empirical
evidence.
-Integration of traditional healers
into home management of
malaria strategies
-Community engagement is of
utmost importance to retain cultural
and contextual sensitivity
aAdapted from References [5, 17, 20, 21, 24, 26, 60]
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The term stakeholder has numerous definitions, many of
which are contextual [28]. Two general definitions are
relevant in the context of IR: the first defines a stake-
holder as a “person or group with an interest, involve-
ment or investment in something” [29]; the second
describes stakeholders as “people who will be affected by
a project, or who can influence it, but who are not dir-
ectly involved in doing the work” [30]. Key stakeholders
in IR may include the government, policy-makers, public
health functionaries, health care providers, health care
managers, financing mechanisms, health care industry,
and the community. Communities may include individ-
uals on who interventions are planned, the broader com-
munity or social structures to which these individuals
belong and the broader society to whom an intervention
may eventually be rolled out. Communities and individualswith specific roles are important stakeholders in the re-
search process. Meaningful engagement with stakeholders
at all levels is crucial in IR, as a means to identify health pri-
orities, to identify key participants, to communicate trans-
parently and effectively about the goals, design, risks,
benefits, and process of a proposed intervention, to gain
trust and develop partnerships to enhance success of the
study, and to gain feedback and identify unforeseen barriers
that could be mitigated at the planning stage [31, 32]. Com-
munity engagement is a related but different concept where
the members of the community who will benefit from or
face the risk of the IR are actively consulted and engaged
with, with the goal that they play an active partnership role
throughout the IR process.
Stakeholder and community engagement are cross-
cutting processes which must be carried out during the
planning, implementation, and post-research phases of
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policy-makers and health financers at the planning stage
include determination that the intervention will address a
local priority health need and to gain buy-in and commit-
ment for the scale-up and sustainability of an effective
intervention. Scale-up is considered by some to be an eth-
ical corollary of IR. Important ethical goals for engage-
ment with communities as partners in planning and
design of IR include to determine acceptability of a pro-
posed intervention, maximize uptake, ensure inclusion of
vulnerable populations, establish accountability processes,
and particularly when individual informed consent is not
feasible due to the research design, to ensure individuals
are aware of the rationale and opt-out possibilities. The
process of decision-making in IR should consider the
power differential between the researchers and the com-
munity and allow adequate representation of the research
participants and the community at large [33–35].
Often community representatives are selected to facili-
tate communication between researchers and the commu-
nity. The selection of community representatives must be
an inclusive and fair process of democratic election or
nomination, guided by the community itself, to ensure ap-
propriate, acceptable, and comprehensive representation
of all sectors of the community irrespective of class, race,
gender, sexual orientation, or ethnicity and to avoid any
potential conflicts of interest-specific individuals may have
[33–36]. Engagement with disadvantaged and marginal-
ized groups is imperative up-front and throughout the IR
process to ensure acceptability and equitable participation
in IR, and importantly, to identify any specific unantici-
pated barriers they may face and to develop strategies to
mitigate further marginalization or stigmatization through
the research [8, 37].
The balance between the risks and benefits
The clinical efficacy and safety of an intervention is gen-
erally known before IR is conducted. In clinical research,
an individual participant can personally weigh the rela-
tive risks and benefits before giving their informed
consent, and the risks and benefits are usually borne by
the same individual. For example, in clinical research
testing, the efficacy of a new vaccine, the benefit of per-
sonal protection, and the risk of side-effects are borne
by the individuals who participate in the study. In IR, for
example in mass drug administration interventions, the
community may benefit from large-scale treatment of
individuals, but an individual may experience side-
effects from a medication they may not personally have
required. In addition, the potential risks of an IR inter-
vention may also result from the modality of implemen-
tation [2]. For example, a community wide public health
screening campaign for sexually transmitted infections
which had been successful in one low-income countrymay carry different risks of stigmatization, religious os-
tracism, and social discrimination if implemented in an
underdeveloped and religiously orthodox country, lead-
ing to a different risk-benefit balance. The risks associ-
ated with IR may not always be obvious up-front as
health systems are complex adaptive systems, and inter-
actions between the components in the health system
are not often clearly understood [38]. Diligent situational
analysis must therefore be conducted during the plan-
ning phase of IR to identify potential risks before harm
is done [19]. In addition, a particular feature of IR is that
at times an intervention is implemented in one group,
but the benefit may accrue to another group [2]. For ex-
ample, IR studying the implementation and uptake prior
to scale-up of a malaria transmission-blocking vaccine
exposes vaccinated individuals to the risks of vaccin-
ation, but unless a large proportion of the community is
vaccinated, the individuals vaccinated will protect others
from malaria transmission, but will not be protected
themselves. How to balance the risks experienced by one
group against the benefits gained by another requires
ethical deliberation and effective communication with
the research participants. The ethical deliberation should
be based on the solidarity principle and should be trans-
parent, involving communities and all stakeholders [39].
To what extent individuals within a group should be ex-
posed to risks for the benefit of others cannot be clearly
defined, but it should be decided based on community
and stakeholder consultations [2]. A line which cannot
be crossed is knowingly exposing one group to harm or
significant risk for the benefit of another.
Ethical concerns in the implementation phase of IR
Autonomy and informed consent
A key principle driving the ethics of clinical research in
humans is individual autonomy. In public health research
autonomy has two dimensions, one concerns individual
autonomy and the other concerns relational autonomy in
the context of the community to which the individual and
the health system belong [40]. Informed consent is the
process through which a research participant can exercise
their autonomy. In clinical research, a fully informed indi-
vidual can determine whether or not they wish to freely
participate in a study and can usually opt-out of the re-
search at any stage. In IR, there may be difficulties in oper-
ationalizing informed consent [2, 20, 41, 42]. For example,
an individual in a cluster in a CRT may not have the
chance to decide and give consent to randomization as
randomization happens at the cluster level. In the case of
non-excludable cluster level, interventions such as envir-
onmental modifications, an individual may not be able to
exercise a meaningful refusal to participate. In such situa-
tions in IR therefore there is a need to articulate informed
consent differently from traditional individual consent in a
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waiver of individual informed consent where the ethical
risks are minimal, and the interventions are largely at a
cluster level (i.e., no individual can opt-out), rendering
refusal meaningless. For example, in an IR study of an
ultraviolet wave system to provide safe drinking water to a
population, the harms are considered minimal, and it is
not possible for any individual participant in a cluster ran-
domized to the intervention arm to easily opt-out of the
study [43]. Such a waiver of consent does not however
preclude the need for meaningful community engagement
and provision of information. At the other end of the
spectrum is the example where individuals have the op-
portunity to refuse participation in the research project,
even though the intervention will occur at the cluster
level. This could occur for example when public health
professionals wish to test whether community health
workers can be trained to provide injections in the com-
munity, and individuals have the option to refuse partici-
pation and visit the health facility to receive the injection
from a nurse. Individual informed consent would be the
norm in this case, even though consent for randomization
cannot be provided by the individual and it is operational-
ized at the cluster level prior to individual contact [20, 43].
In the middle of the spectrum is dual consent from gate-
keepers and individuals. Community agreement relies on
the identification of an appropriate gatekeeper, who
should have a keen interest in the welfare of the commu-
nity and represents the community in a fair manner [36].
There are several challenges in selection of the gatekeeper.
In traditional communities where collective decision-
making is practiced, selection of a gatekeeper may not be
problematic. But in more complex societies, or more com-
plex studies, selection of one voice to represent the com-
munity is often challenging. The community leader may
not be the most appropriate person to make decisions on
whether a community or its members should participate
in a study or not. For example, an elderly male village
leader may not be an appropriate gatekeeper to consent to
an IR intervention on pregnant women in his community.
Selecting community representatives fairly requires inclu-
sion of a variety of representative stakeholders, especially
those from the target groups, and ensuring transparency
of the process [20, 36]. The agreement of the gatekeeper,
however, cannot replace individual consent or assent
where relevant as discussed above [4]. Ultimately, it is im-
portant that proper ethical oversight is in place through
Institutional Ethics Committees to ensure that the appro-
priate informed consent process is followed, maximally re-
specting autonomy of individuals in the study [44].
Challenges in operationalizing informed consent in the
context of IR also include whether the beneficiaries are
individuals or populations, and appropriate identification
of who the actual research participants are [18]. Forexample, when implementing a taxi voucher system to
increase the rates of institutional deliveries and reduce
maternal mortality, should consent be obtained from the
pregnant women, the taxi drivers, or the health care
workers whose performance will also be evaluated? The
Ottawa statement on ethical conduct of cluster random-
ized controlled trials define a research participant as: the
intended recipients of the experimental or control inter-
vention; the direct targets of experimental or control en-
vironmental alterations; persons with whom researchers
interact to collect their data; persons whose identifiable
private information is accessible to the researcher for
collection of their data [21]. As such, in the example
above, patients and health care workers should provide
consent, but whether this should extend to the taxi
drivers is questionable and may be difficult to
operationalize. A further important ethical issue in the
informed consent process is the extent of information to
be revealed to the participants in the intervention and
control arms, where applicable. In IR, especially when
behaviour change interventions are being studied, know-
ledge of the intervention itself may change the outcomes
and implementation process. There is, therefore, often
the need to conceal some information about the inter-
vention. The ethical justification for this is debatable,
and it must be balanced against the risks/benefits and
the potential impact on study validity as discussed in the
CIOMS guidelines [45]. The informed consent process
in IR therefore may be quite different from that in clin-
ical research and requires thorough consideration to en-
sure optimal ethical conduct of IR.
Privacy and confidentiality
Particular issues relating to privacy and confidentiality in
IR relate to the fact that IR often requires that facility
level data on patient outcomes be available or that indi-
vidual level data from facility health records be obtained.
For example, if a public health intervention is imple-
mented to regulate institutional deliveries and improve
the quality of skilled institutional deliveries, there may
be interventions at the health facility level, but confiden-
tiality restrictions on access to data from women who
deliver in the facilities may hamper effectiveness analyses
of the health system impact [19]. In such cases, the data
that is obtained from facilities should either be anon-
ymized, or the individuals about whom data is being
sought should provide consent for their data to be
reviewed by the researchers. Where such consent is not
possible, it is the responsibility of the researcher to ob-
tain a waiver of consent from the respective ethics
board, and put in place mechanisms to ensure that the
confidentiality of the patient information is respected. A
proactive strategy of informing patients about potential
data collection for research and quality improvement
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and confidentiality could also serve strengthen the
patient-researcher partnership and build trust [46].
Standard of care or prevention
There are two approaches to decide on standard of care
or prevention to be given to a control group [47–49]. One
approach is to allocate the local de facto existing standard,
which in some situations may be grossly insufficient,
making it ethically unacceptable based on justice and
fairness principles. For example, in an IR trying to study
prevention of mother to child transmission of HIV in a
country where routine anti retroviral therapy is not avail-
able, the local de facto standard of care is no treatment.
Having a placebo control arm in the study is not accept-
able in spite of the local de facto care being no treatment,
because an effective treatment which reduces transmission
is available and should be accessible to the mothers. The
second approach is to provide the local de jure standard
of care or prevention, which is agreed upon by public
health experts of that region and is acceptable to the com-
munity. This approach may still be unfair in that this
standard may be unsustainable for the local health system
after the IR is completed. For example, in a public health
behaviour change implementation study focused on hand
washing among schoolchildren, the intervention group re-
ceives a school-based lunchtime hand washing program,
and the control group receives soap and water in all
schools, but without any emphasis on hand washing be-
fore eating. In this case, the standard of care is provision
of hygiene tools, and the intervention is emphasizing the
use of these tools. In this context, allowing the control
group to have no intervention can be considered ethical.
The consideration of standards of care or prevention may
therefore identify new gaps as targets for future IR.
Ancillary care
Ancillary care refers to the identification of problems
that may contribute to ill-health that are beyond the
scope of the study in question, for example, researchers
studying home management of malaria may come across
household members with other diseases needing atten-
tion [11, 50, 51]. Sometimes ancillary care responsibil-
ities can be foreseen at the design stage and at others
they are encountered only during the conduct of the IR.
Ancillary care obligations are present when the need is
serious in terms of severity or urgency or both and when
there is a possibility of provision of care within the scope
of the research [11]. For example, in the school-based
hand washing behaviour change IR study, uninterrupted
tap water supply may be lacking and this is an ancillary
care requirement. However, this example illustrates that
it may not be realistic to expect implementation re-
searchers to assume all ancillary care responsibilities.Researchers may not have the expertise to provide the
ancillary care; the provision of the care may be costly or
may require system-level interventions. The researchers
must, however, establish process of accountability for an-
cillary care need identified through the research, deter-
mine which needs may realistically fall within the scope
of responsibility of the researchers, and proactively en-
gage with the local government or non-governmental or-
ganizations during the planning and conduct phases of
IR to identify who will be able to meet other needs [52].
Research capacity and health system strengthening
Well conducted IR should lead to strengthening of re-
search capacity of the local institutions as well as individ-
uals’ capacity to conduct research in settings where such
capacity is weak [53]. Research capacity strengthening can
range from creating a trained workforce of researchers
and research volunteers up to training and capacity build-
ing of research experts and infrastructure to permit inde-
pendent conduct of locally responsive IR in the future.
Based on the need in the area where the IR is being con-
ducted, appropriate research capacity strengthening
should be facilitated. This can be facilitated by appropriate
stakeholder engagement ensuring commitment by donors
and governments to build sustainable research capacity.
Not only is it important for the IR to strengthen local re-
search capacity, it should also strengthen the health sys-
tem within which it is conducted. For example, true
partnership in an implementation research study of rapid
diagnosis of tuberculosis resistance should build sustain-
able infrastructure in technology required, expertise to
run and maintain the technology, strengthen the local
health information system to track data acquired, train
local researchers in design, conduct, analysis and reporting
of study findings as well as participation in post-
intervention scale-up, thereby strengthening the local re-
search and health system capacity. IR projects focusing on
specific health gaps may, however, create vertical program
structures within the health system which may be disem-
powering to the system through inefficient resource
utilization [13]. It is ethically important that the conduct
of IR should focus on horizontal integration of public
health interventions into the health system such that a
project empowering any component of the health system
may have positive repercussions for the entire system.
Strengthening the capacity to translate research findings
into health policy is a specific imperative in IR and must
be a component of all phases of the IR process [53].
Ethical concerns in the post-research phase of implemen-
tation research
Dissemination of research findings
Given the important public health impact of IR, there is
an ethical obligation to disseminate the research findings
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stakeholders who participated in the research [54, 55]. If
an implementation strategy had a negative or positive
impact in a certain context, either finding may be im-
portant for researchers planning similar interventions
elsewhere. Therefore, irrespective of the results, the find-
ings of the IR should be disseminated. Furthermore, re-
source utilization globally could be enhanced by an
imperative for dissemination of IR findings, as once an
intervention has been tested in many different local con-
texts, its findings may be presumed to be generalizable
and obviate the need for new IR studies and delays in
scaling-up of the intervention in new contexts.
Data ownership and sharing
In case of donor or sponsor-driven IR, data is often
owned donor, who may regulate and restrict further
handling of the data. Data ownership should be fairly ne-
gotiated through transparent stakeholder engagement in
the planning phase of IR, and ethical oversight of the
data ownership process is required to ensure appropriate
access to the research findings by the relevant stake-
holders post-study, including the local researchers and
communities when appropriate, to maximize the utility
of the knowledge generated. It may be acceptable for re-
searchers or donors to own data without further respon-
sibility. However, given the policy and public health
implications of IR and the necessity of trust especially
with the communities, there may be a responsibility for
data sharing which should also be negotiated up-front,
considering the important implications of protecting
privacy and confidentiality as well as to allow strength-
ening of local research capacity.
Translating findings into public health action
Due to the inherent nature of IR, there is an ethical obli-
gation for IR findings to be used to inform effective and
equitable public health action. This necessitates timely
consideration and uptake as relevant of the IR findings
into public health policy and practice. Potential barriers
to translating knowledge into action include lack of prior
consultation with policy-makers, lack of funding, weak
health systems, poor communication of findings by re-
searchers to policy-makers, and absence of a culture of
evidence-based decision-making among others [53].
Therefore, in order to translate the research into public
health action, implementation researchers should engage
with policy-makers and health system officials, import-
ant stakeholders in IR, upfront to ensure commitment
to sustainability should the intervention prove success-
ful, and must communicate their research findings
rapidly, clearly, and concisely to engage and inform
policy-makers in a timely fashion. Researchers should
also propose actionable suggestions based on theresearch findings to facilitate uptake and scale-up of suc-
cessful interventions. Barriers identified during IR may
require further study to develop strategies to overcome
them. Effective communication between researchers and
policy-makers, as well as education of the public are im-
portant social justice obligations in IR, ensuring that ex-
pectations raised during the research are met, and those
who participated as control subjects gain access to inter-
ventions withheld from them during the study.
Scalability and sustainability
Scalability and sustainability are important ethical con-
siderations at both planning and post-study phases, as
ultimately these are the goals of IR [13, 56]. The duty to
ensure sustainability post-study cannot only lie with the
researchers. Multiple stakeholders must come together
to promote this goal which requires ongoing stakeholder
engagement throughout the IR process. The researchers
should ensure through effective engagement during the
planning and conduct stages of IR that the non-research
stakeholders such as policy-makers, local providers, and
health system officials remain committed to sustaining
implementation of an intervention if found to be effect-
ive. If access to a proposed public health intervention
cannot be ensured for a community after the IR, it may
not be ethical to carry out such a research activity. If
specific interventions are provided during IR without a
plan for sustainability, this could lead to exacerbation of
inequity and harmful effects to the community as well as
loss of trust in the health system.
Benefit sharing
Irrespective of the context in which IR is conducted,
LMIC or developed countries, there is an ethical obli-
gation to share benefits of the IR with the community
[57]. There are various classifications of the benefits
that can be achieved as a result of conduct of the IR.
The benefits may be direct as a result of the interven-
tion being studied, or indirect and not related to the
intervention per se. The benefits may accrue to indi-
vidual participants or to the community at large. For
example, IR may be conducted in communities where
the local health system is weak, therefore success of an
intervention may result in introduction of a new inter-
vention that was effective in the local context, provid-
ing individual benefit. In addition, the IR likely
identified and overcame barriers which would have
contributed to some strengthening of the local health
system that would have a broader impact. IR re-
searchers can facilitate sharing of direct benefits by ad-
vocating for sustainable translation of research
findings into action, and sharing of indirect benefits
through building research capacity and health system
strengthening. The unique nature of IR where the
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the ones who enjoy the benefits is a challenge as dis-
cussed above. Optimal benefit sharing can be pro-
moted through proper pre-IR planning and ethical
conduct. Community and stakeholder engagement
plays an important role in achieving benefit sharing as
when adequately informed they can advocate for ac-
cess to proven benefits. Benefit sharing has important
social justice implications, and it is the obligation of
the researcher to achieve a balance of risks and bene-
fits to both individuals and communities [58, 59].
Conclusion
Putting public health evidence into practice in specific
populations requires the generation of knowledge about
the feasibility of public health interventions within a spe-
cific context, the relative harms and benefits, how an
intervention is taken up, whether it reaches the most
vulnerable populations, and the logistics of the imple-
mentation process. IR aims to generate this knowledge
with the goal of enhancing health system performance
while upholding fairness and justice in the reach of the
intervention to all parts of the community. The ethical
principles pertaining to IR are not unique to IR, but may
require adaptation in application given the particularities
of IR. The stakes of IR are high because of the research
contexts within fragile health systems, the large numbers
of subjects involved and the reduced ability to predict
outcomes and consequences as compared to clinical re-
search [8]. Awareness of the ethical challenges relating
to IR is important throughout the planning, implemen-
tation, and post-study phases of the research not only to
ensure studies are conducted appropriately and that re-
sults are maximally useful, but is also important for eth-
ics review committees and institutional review boards to
provide appropriate and insightful review of IR projects.
This paper emerged out of the development of the
Ethics in Implementation Research Toolkit. Through the
consultation process, an important need was identified
to clarify the differences in the application of research
ethical principles between clinical research and IR, both
to guide researchers in planning and conduct of IR and
to facilitate review of IR proposals by research ethics
committees. As such, this paper complements the Im-
plementation Research Toolkit (http://www.who.int/tdr/
publications/topics/ir-toolkit/en/) and the Framework
for Operations and Implementation Research in health
and Disease Control Programs (http://www.who.int/hiv/
pub/operational/or_framework.pdf ). It is hoped that this
paper will generate discussion in further refining roles
and obligations of implementation researchers in low re-
sources settings and in further defining the obligations
of policy-makers and funders in committing to long-
term sustainability of successful interventions.Endnotes
1PAR is a community-based approach to research that
emphasizes community participation in research design,
data collection, analysis, and interpretation. PAR tries to
understand situations and phenomena by changing them
and making observations. The experimentation is
grounded in community wisdom and experience.
2Effectiveness implementation hybrid designs include
simultaneous testing of clinical effectiveness and effect-
iveness of the method of implementation. It may be of
three types: (1) primarily doing an effectiveness study
while at the same time gathering data on implementa-
tion, (2) primarily doing an implementation study while
simultaneously gather data on effectiveness, or (3) dual
testing of both effectiveness and implementation
strategies.
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